Effect of Fucoxanthin on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion [2023]

The aim of this study was to evaluate the effect of fucoxanthin on
metabolic syndrome (MetS), insulin sensitivity, and insulin secretion. A randomized, double-blind, placebo-controlled clinical trial was conducted in 28 patients diagnosed with MetS. Patients were randomly assigned to receive 12 mg of fucoxanthin or placebo once a day for 12 weeks.

In conclusion, fucoxanthin administration leads to a decrease
in body weight, body mass index, weight circumference, blood pressure, triglycerides,  as well as increase in the first phase of
insulin secretion and total insulin secretion in patients with MetS.
Clinical Trial Registration number: NCT03613740.